Luminopia, Inc.

Luminopia, Inc. specializes in vision training software, which includes digital platforms like Luminopia and Luminopia One. These products are designed to enhance visual processing and perceptual skills, targeting conditions such as amblyopia (lazy eye) and strabismus (misaligned eyes) in both pediatric and adult patients. The software uses structured exercises to improve visual function through interactive training.

Luminopia, Inc. is based in the United States, and its vision training software devices are regulated under FDA jurisdiction. Since these products fall under Class II classification, their authorisation is granted through the 510(k) pathway, which demonstrates substantial equivalence to a legally marketed predicate device. This ensures compliance with FDA requirements for digital health interventions.

Luminopia’s vision training software devices are listed in the FDA’s Unique Device Identifier (UDI) database, which provides a standardized identification system for medical devices. Additionally, the company’s products have undergone 510(k) clearance, meaning they are documented in the FDA’s 510(k) submission registry as authorised medical devices under US regulations.

Luminopia’s vision training software is classified as Class II medical devices by the FDA. This classification is based on the risk level of the product—Class II devices require special controls to ensure safety and effectiveness beyond general controls (like good manufacturing practices) but do not pose the highest risk (reserved for Class III). The structured, evidence-based approach of these digital interventions justifies their regulatory categorisation.